key: cord-0021255-qwyor074
authors: Yin, Xiaomin; Qiu, Yanyan; Zhao, Chenhao; Zhou, Zheng; Bao, Junze; Qian, Wei
title: The Role of Amyloid-Beta and Tau in the Early Pathogenesis of Alzheimer’s Disease
date: 2021-09-02
journal: Med Sci Monit
DOI: 10.12659/msm.933084
sha: 2f0cc90a49522bed28bc7e0e0629f90ed1392507
doc_id: 21255
cord_uid: qwyor074

The abnormal accumulation of amyloid-β (Aβ) and neurofibrillary tangles (NFTs) containing phosphorylated tau proteins are the main histopathological feature of Alzheimer’s disease (AD). Synaptic damage and loss are earlier events than amyloid plaques and NFTs in AD progress and best correlate with cognitive deficits in AD patients. Soluble oligomeric Aβ initiates the progression of AD and tau mediates the subsequent synaptic impairments at an early stage of AD. In this review we discuss how Aβ or/and tau causes synaptic dysfunction. Aβ oligomers gather at synapses and give rise to synaptic death in a variety of ways such as regulating receptors and receptor tyrosine kinases, unbalancing calcium homeostasis, and activating caspases and calcineurin. A large amount of hyperphosphorylated tau exists in the synapse of the AD brain. Aβ-triggered synaptic deficits are dependent on tau. Soluble, hyperphosphorylated tau is much more correlated to cognitive decline in AD patients. Tau-targeted therapies have received more attention because the treatments targeting Aβ failed in AD. Here, we also review the therapy strategies used to intervene in the very early stages of AD. Soluble hyperphosphorylated tau forms a complex with cell surface receptors, scaffold proteins, or intracellular signaling molecules to damage synaptic function. Therefore, therapeutic strategies targeting synaptic tau at the early stage of AD may ameliorating pathology in AD. This review aims to provide an update on the role of oligomeric Aβ and soluble hyperphosphorylated tau in the early pathogenesis of Alzheimer’s disease and to develop a new treatment strategy based on this.

Alzheimer's disease (AD) is characterized by two hallmark pathological lesions in the brain: the extracellular amyloid plaques deposition of amyloid-b (Ab) peptides and intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau [1, 2] . The internal relations between these two hallmarks and the cognitive dysfunction occurred in AD patients remain elusive [3] . Accumulation of toxic Ab is proposed as one of the important early events in AD, but unsuccessful clinical trials based on Ab-targeting drugs have triggered researchers to investigate new therapeutic strategies targeting alternative disease mechanisms [4] . Ab oligomers but not amyloid plaques target the postsynaptic compartment of excitatory synapses with high affinity, changing the structure and function of synapses [5] . More and more research indicates that the pathology of tau correlates with cognitive defects in AD [6] . However, soluble forms of tau oligomers but not NFTs appear to be an important factor inducing neuronal dysfunction and cognitive impairment [7, 8] . Memory deficits highly correlate with synaptic decline in the hippocampus of AD patient's brains [9] [10] [11] . Synaptic loss is the first indicator of AD progression, even in the earliest of stage, called mild cognitive impairment (MCI), and has the strongest biological correlation with cognitive deficits found in AD patients [12] [13] [14] . Mislocalization of tau to dendrites, which is an early event in AD pathogenesis prior to tau aggregation, is a neuropathological feature of AD brains [15, 16] . Synaptic tau correlates with the onset of cognitive decline in AD [17, 18] . This review aims to provide an update on what is currently known about the role of Ab and tau in the early pathogenesis of Alzheimer's disease.

Long-term potentiation (LTP) and long-term depression (LTD), which are forms of activity-dependent synaptic plasticity, and the formation of dendritic spines are considered to underlie learning and memory [19] . LTP increases in synaptic strength depend on activating NMDA receptors by recurring synaptic activity. In contrast, LTD reduces synaptic activity through phosphorylation of AMPA receptors [20] .

Synaptic loss can be induced by oligomeric forms of Ab [1, 21, 22] , suggesting that Ab is a driver of synaptic dysfunction in AD [23] . The senile plaques were considered to be the major pathogenic substance in AD, but clinical investigations did not reveal a strong association between extracellular amyloid plaque and cognitive defects [24] . During AD progress, Ab oligomers begin to be enriched at synapses, which is earlier than the formation of amyloid plaques or accumulation of phosphorylated tau at synapses [25, 26] . Extracellular Ab accumulates around the postsynaptic compartment more abundantly than at presynaptic terminals [27] .

Accumulated research results indicate that Ab causes synaptic death, LTD and LTP via modulating excitatory receptors and receptor tyrosine kinases, unbalancing calcium homeostasis, and activating caspases and calcineurin. Ab binds to AMPA receptors and causes their internalization, leading to increased LTD. Ab binds to 7a-nicotinic acetylcholine receptors, leading to an internalization of NMDA receptors and LTD [28] . Oligomeric Ab stimulates NMDA receptors to upregulate calcium and redox reactions, leading to synaptic dysfunction and neuronal loss [29] . Calcineurin, activated by Ab elevated calcium, dephosphorylates actin filaments to cause dendritic spine loss. Calcineurin activation can also reduce NMDA receptor expression on the surface and lead to greater AMPA receptor internalization. Soluble Ab dephosphorylates AMPA receptors and increases receptor internalization. Oligomeric Ab also binds with tyrosine kinases to modulate NMDA receptor trafficking and reduce LTP [30] .

Oligomeric Ab can impair LTP while increasing LTD in a concentration-dependent manner. Low levels of oligomeric Ab facilitate LTP, but high levels of Ab impair it [29] by affecting calcium channel activity and glutamate receptor-dependent signaling pathways [31] .

The increased NMDA activity stimulated by oligomeric Ab can lead to increased tau accumulation. Increased phosphorylated tau associates with, and further amplifies, the dendritic spine loss [32] . Age-dependent accumulations of Ab and tau and their interactions at synapses largely impair synaptic activity via altering LTP and LTD levels [30] .

Tau normally exists in synapses of both healthy and AD brains, while there is a greater level of hyperphosphorylated tau present in the AD synapse [33] . Soluble, hyperphosphorylated tau is much more closely related to synaptic dysfunction and cognitive decline in AD patients compared to Ab and aggregated tangles of tau [34] . In vivo experiments showed the role of tau in synaptic plasticity. Reduction or depletion of tau blocked the induction of LTD but not LTP. Replacement of endogenous tau with human tau restored LTD. These data support the essential role of tau in a NMDAR-dependent LTD in the hippocampus [35] . Tau's role in LTD depends on its phosphorylation at serine 396, which internalizes the AMPA receptor [36] . Reducing the phosphorylation of tau by inhibiting tau kinases rescues tau-dependent LTP deficits and alleviates synaptic loss in tau transgenic mice [37, 38] . Ab may need tau to impair LTP, since tau-null mice showed no impairment in LTP when Ab was applied [29] . Synaptic deficits induced by Ab were closely related with tau, since reducing endogenous tau levels in Ab-forming AD mouse models prevented dysfunctions [39] [40] [41] [42] . In contrast, e933084-2 overexpression of human tau in amyloidosis mouse models increased synaptic loss and memory impairment [40, 43] .

Transgenic mice with human P301S or P301L mutant tau had impaired LTP in the hippocampus [18, 44] . Mice expressing human V337M mutant tau had reduced excitatory synaptic transmission, associated with decreased synaptic glutamate receptors levels in both the ventral striatum and the insular cortex [45] . In cortical neurons, expression of human P301L mutant tau resulted in mushroom spine loss [46] .

Mitochondria serves as energy supplier for synaptic functions such as synaptic transmission, synaptic outgrowth, and synaptic vesicle formation [47, 48] . Ab or phosphorylated tau triggers damage and transportation of mitochondria to synaptic terminals, which may provide low levels of ATP to synapses, leading to synaptic degeneration [30] . Mitochondrial dysfunction occurs early in AD progression [49] . Synapse loss is an early event of AD, which is attributed to soluble Ab, phosphorylated tau, and increased free radicals generated by mitochondria at synapses [30] . More abnormal mitochondria are found in synapses of AD brains compared to healthy brains [50] .

Extensive studies on synaptic proteins in a large number of healthy controls and AD patients reveal that postsynaptic and presynaptic proteins are important for synaptic function and may be related to cognitive impairments in AD [51] . Synaptophysin, a presynaptic protein, was decreased by around 25% in MCI patients, which can occur before Ab plaque formation. Loss of synaptophysin correlates with cognitive decline and is also a marker for disease progression in AD patients [11] . The postsynaptic density-95 (PSD-95) protein is the most abundant scaffold proteins inside the postsynaptic density (PSD), a densely packed multi-protein structure for synaptic formation and function at the distal tip of dendritic spine heads [52] [53] [54] . PSD-95 is crucial for trafficking and anchoring of synaptic glutamate receptors [55] [56] [57] [58] . It is predicted that tau, Fyn, PSD-95, and NMDARs form a protein complex at the synapse [59] . Loss of PSD-95 results in decrease of synapses containing glutamate receptors and impairments in AMPAR and NMDAR transmissions [60] . It has been reported that the expression of PSD-95 is aberrant in several human disorders, including AD [61] [62] [63] [64] [65] . Researchers identified postmortem synapse and synaptic marker loss from AD patients in a meta-analysis [66] .

The "inflammation hypothesis" [67] , "cholinergic hypothesis" [68] , and "amyloid cascade hypothesis" [69] are three important hypotheses on the etiopathogenesis of AD. Several microbes, such as human herpesviruses, spirochetes, Chlamydia pneumoniae, and Borrelia burgdorferi, have been proposed as triggers of AD [70] . Infections may induce the generation of Ab in the brain [71] . The antiviral property of Ab could protect the brain from infection [72] .

Oxidative stress (OS) plays a critical role in AD pathogenesis [73, 74] . Oxidative stress promotes both tau hyperphosphorylation and Ab deposition and then the loss of synapses and neurons [75] .

Prions are defined as host-encoded proteins that adopt alternative conformations and are self-propagating [76] . Both Ab and tau are found to have prion features in AD [77] . Tau prions has been shown to spread throughout the brain along known neuroanatomical pathways over the course of AD [78] .

Activated proinflammatory cytokines by the altering of gut microbiota increase intestinal permeability and lead to insulin resistance that is associated with AD [79] . Ab oligomers translocating from the gut to the brain contribute to the onset of AD and neuroinflammation [80] . Eubacterium rectale, Porphyromonas gingivalis, and Lactobacillus rhamnosus are important in the origination of AD [81] [82] [83] [84] [85] .

Astrocytes are key components of the neurovascular unit (NVU) [86] . In pathological situations, astrocytes turn into reactive astrocytes undergoing a series of morphological and functional alterations. Reactive astrocytes are typically found in the region with high Ab or tau pathology in postmortem AD brains [87] [88] [89] . Reactive astrocytes release cytokines, inflammatory factors, and reactive oxygen species (ROS), thus contributing to neuroinflammatory changes in AD [90] .

Genome-wide association studies (GWAS) identified the gene triggering receptor expressed on myeloid cells 2 (TREM2) that e933084-3 are associated with a high risk of AD [91] . TREM2, a microglia surface receptor, is especially highly expressed in microglial cells [92, 93] . The R47H and D87N TREM2 mutation confer significant risk of AD in humans [91, 94] . Soluble TREM2 levels are related to levels of total tau and phospho-tau in cerebrospinal fluid (CSF), but not to Ab1-42 levels in AD brains [95] [96] [97] [98] .

Synaptic deficiency is an early sign of AD pathogenesis and is closely correlated with the cognitive decline in AD. Oligomeric Ab or soluble hyperphosphorylated tau interacts with cell surface receptors, scaffold proteins, or intracellular signaling molecules to destroy synaptic structure and function. Therefore, therapeutic strategies targeting synaptopathy at the early stage of AD may ameliorate pathology in AD [99] . To date, no effective intervention alleviating Ab load has been developed, although oligomeric Ab is the main factor involved in the synaptotoxicity in AD. It is more important to find Ab species-specific interventions [100] . For example, Ab*56 identified in the brains and CSF of people with normal cognitive function triggers a specific intracellular response to hyperphosphorylated tau through CaMKIIa but not GSK-3b or Cdk5. Ab*56 or its downstream signaling cascades may be promising targets for early-stage AD interventions [101] . Moreover, because APP processing is regulated by neuronal activity, enhancing synaptic function, which prevents synaptic dysfunction and reduces Ab production, could have a dual beneficial effect in reversing AD progression [3] . Since tau is more closely associated with cognitive decline than Ab in the AD brain, great efforts have been made to explore tau-focused therapeutic interventions [102] , and approaches focusing on pathological tau removal have been developed. Antibody-mediated [103] [104] [105] [106] or anti-sense oligonucleotide (ASO)-mediated tau reduction [107] successfully reduced synaptic dysfunction and cognitive deficits in AD animal models. Drugs which aim at new molecular targets related to dendritic and postsynaptic tau need more exploration. Since the synaptotoxicity of Ab is mediated by receptor complexes, multiple strategies have been developed to target these cell surface proteins and their downstream signaling pathways. Extracellular regulation of the activity of these receptors makes them more accessible targets for AD treatment.

Synaptic defects closely associated with cognitive decline are considered the early events in AD pathogenesis. Based on a large number of studies, soluble Ab oligomers appear to be the primary cause of synaptic dysfunction, and synaptic tau seems to be the indispensable mediator in the process (Figure 1) . Ab oligomers affect LTP, LTD, and synaptic death by acting on receptors, unbalancing calcium homeostasis, and activating caspases and calcineurin. Soluble hyperphosphorylated tau impairs synaptic function by interacting with scaffold proteins, cell surface receptors, or intracellular signaling molecules. Ab or phosphorylated tau also triggers synaptic degeneration via damaging and transportation of mitochondria.

However, further investigations are still needed to answer key questions: 1) Why have therapeutic strategies targeting Ab all failed if Ab oligomers are the initiator of AD's early pathology? 2) Why is synaptic tau required in the synaptotoxicity attributed to Ab? In the future, a combination therapy targeting synaptic tau and Ab together may be a potential therapeutic approach for AD patients at the very early stage.

All figures submitted have been created by the authors, who confirm that the images are original with no duplication and have not been previously published in whole or in part. and tau in the progress of Alzheimer's disease. Soluble oligomeric Ab is the primary cause of synaptic dysfunction, whereas synaptic tau is the mediator in the progress. They locate in the synapse and work with receptors, synaptic proteins, and mitochondria to cause synaptic dysfunction, and ultimately lead to cognitive deficits. During the pathogenesis of AD, this is the early event, which occurs long before the formation of neurofibrillary tangles and senile plaques.

e933084-4 

Amyloid-beta and tau -a toxic pas de deux in Alzheimer's disease

Alzheimer's disease

Synaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic strategies

The complexity of tau in Alzheimer's disease

Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques

Neuropathological alterations in Alzheimer disease

Tau suppression in a neurodegenerative mouse model improves memory function

Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic Tau mutant

Hippocampal pathology reflects memory deficit and brain imaging measurements in Alzheimer's disease: Clinicopathologic correlations using three sets of pathologic diagnostic criteria

Alzheimer's disease: Cell-specific pathology isolates the hippocampal formation

Alzheimer's disease is a synaptic failure

Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment

Immunoelectron microscopic study of synaptic pathology in Alzheimer's disease

Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment

The pathological process underlying Alzheimer's disease in individuals under thirty

Synaptic tau seeding precedes tau pathology in human Alzheimer's disease brain

Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity

Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model

The molecular and systems biology of memory

How to scale down postsynaptic strength

Pathways by which Abeta facilitates tau pathology

Neurotoxicity of amyloid beta-protein: Synaptic and network dysfunction. Cold Spring Harb Perspect Med

Dendritic tau in Alzheimer's dfisease

Alzheimer's disease

Synaptic amyloid-beta oligomers precede P-tau and differentiate high pathology control cases

Pre-plaque conformational changes in Alzheimer's disease-linked Abeta and APP

Synaptic impairment in Alzheimer's disease: A dysregulated symphony

Alzheimer's disease: Synapses gone cold

Synaptic changes in Alzheimer's disease and its models

Synaptic basis of Alzheimer's disease: Focus on synaptic amyloid beta, P-tau and mitochondria

Amyloid-beta and phosphorylated tau accumulations cause abnormalities at synapses of Alzheimer's disease neurons

Functional polymorphisms of the CCL2 and MBL genes cumulatively increase susceptibility to severe acute respiratory syndrome coronavirus infection

Co-localization of amyloid beta and tau pathology in Alzheimer's disease synaptosomes

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

Microtubule-associated protein tau is essential for long-term depression in the hippocampus

Tau phosphorylation at serine 396 residue is required for hippocampal LTD

Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human Tau

Inhibition of p25/Cdk5 attenuates tauopathy in mouse and iPSC models of frontotemporal dementia

Tau exacerbates excitotoxic brain damage in an animal model of stroke

Dendritic function of tau mediates amyloidbeta toxicity in Alzheimer's disease mouse models

Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model

Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease

Synergistic effects of amyloidbeta and wild-type human tau on dendritic spine loss in a floxed double transgenic model of Alzheimer's disease

Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration

Tau-mediated NMDA receptor impairment underlies dysfunction of a selectively vulnerable network in a mouse model of frontotemporal dementia

Electrophysiological changes precede morphological changes to frontal cortical pyramidal neurons in the rTg4510 mouse model of progressive tauopathy

Mitophagy regulates integrity of mitochondria at synapses and is critical for synaptic maintenance

Amyloid beta, mitochondrial dysfunction and synaptic damage: Implications for cognitive decline in aging and Alzheimer's disease

Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: Implications to mitochondria-targeted antioxidant therapeutics

Region-specific depletion of synaptic mitochondria in the brains of patients with Alzheimer's disease

Differential loss of synaptic proteins in Alzheimer's disease: Implications for synaptic dysfunction

Isolation and characterization of postsynaptic densities from various brain regions: Enrichment of different types of postsynaptic densities

Organization of the core structure of the postsynaptic density

The postsynaptic organization of synapses

PSD-95 family MAGUKs are essential for anchoring AMPA and NMDA receptor complexes at the postsynaptic density

Synaptic trafficking of glutamate receptors by MAGUK scaffolding proteins

Regulation of AMPA receptor surface diffusion by PSD-95 slots

Synaptic targeting and function of SAPAPs mediated by phosphorylation-dependent binding to PSD-95 MAGUKs

Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: Randomised controlled trial

Synaptic consolidation normalizes AMPAR quantal size following MAGUK loss

The SH3 domain of postsynaptic density 95 mediates inflammatory pain through phosphatidylinositol-3-kinase recruitment

Glutamatergic postsynaptic density protein dysfunctions in synaptic plasticity and dendritic spines morphology: Relevance to schizophrenia and other behavioral disorders pathophysiology, and implications for novel therapeutic approaches

A framework to understand the variations of PSD-95 expression in brain aging and in Alzheimer's disease

Motor impairments, striatal degeneration, and altered dopamine-glutamate interplay in mice lacking PSD-95

Complement and microglia mediate early synapse loss in Alzheimer mouse models

Meta-analysis of synaptic pathology in Alzheimer's disease reveals selective molecular vesicular machinery vulnerability

Deciphering the mechanism underlying late-onset Alzheimer disease

The cholinergic hypothesis of geriatric memory dysfunction

Amyloid deposition as the central event in the aetiology of Alzheimer's disease

Are infections seeding some cases of Alzheimer's disease?

Protective effect of amyloid-beta peptides against herpes simplex virus-1 infection in a neuronal cell culture model

Alzheimer's associated beta-amyloid protein inhibits influenza A virus and modulates viral interactions with phagocytes

Oxidative stress, amyloid-beta peptide, and altered key molecular pathways in the pathogenesis and progression of Alzheimer's disease

Oxidative stress in neurodegenerative diseases

Oxidative stress in Alzheimer's disease

Expanding spectrum of prion diseases

New insights into the pathogenesis of Alzheimer's disease

Neuropathological stageing of Alzheimer-related changes

Impact of microbiota on central nervous system and neurological diseases: The gut-brain axis

Intra-gastrointestinal amyloid-be-ta1-42 oligomers perturb enteric function and induce Alzheimer's disease pathology

Assessment of probiotics mixture on memory function, inflammation markers, and oxidative stress in an Alzheimer's disease model of rats

d-glutamate and gut microbiota in Alzheimer's disease

Bacterial infection causes stressinduced memory dysfunction in mice

Porphyromonas gingivalis periodontal infection and its putative links with Alzheimer's disease

Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly

The neurovascular unit coming of age: A journey through neurovascular coupling in health and disease

Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease

)H-deprenyl and (3)H-PIB autoradiography show different laminar distributions of astroglia and fibrillar beta-amyloid in Alzheimer brain

Cortical laminar tau deposits and activated astrocytes in Alzheimer's disease visualised by (3)H-THK5117 and (3)H-deprenyl autoradiography

Neuroglia in neurodegeneration

Variant of TREM2 associated with the risk of Alzheimer's disease

The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease

Coding variants in TREM2 increase risk for Alzheimer's disease

TREM2 variants in Alzheimer's disease

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease

Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status

sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers

Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease

Alzheimer's disease

Memantine rescues transient cognitive impairment caused by high-molecular-weight abeta oligomers but not the persistent impairment induced by low-molecular-weight oligomers

The amyloid-b oligomer Ab*56 induces specific alterations in neuronal signaling that lead to tau phosphorylation and aggregation

Somatodendritic accumulation of Tau in Alzheimer's disease is promoted by Fyn-mediated local protein translation

Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model

Early events in Alzheimer's disease

Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer's disease mouse model

Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice

Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo

Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy